pembrolizumab
Pembrolizumab is a drug used to treat Melanoma, Non-small Cell Lung Cancer, Breast Cancer, and other conditions. Pembrolizumab is being actively studied in 808 studies and prior, has been studied in 111.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Merck Sharp & Dohme Corp. | Memorial Sloan Kettering Cancer Center | Sara Tolaney |
| M.D. Anderson Cancer Center | Dana Farber Cancer Institute | CCTU |
| National Cancer Institute (NCI) | Massachusetts General Hospital | David Reardon, MD |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
- Stage IIIA Non-Small Cell Lung Cancer
- Cisplatin
- +3 more
- Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
2021-07-06
Jul 6, 2021M
Not yet recruiting
- Thyroid
- Pembrolizumab
- Houston, TexasM D Anderson Cancer Center
2021-10-05
Oct 5, 2021N
Not yet recruiting
- Metastatic Head and Neck Cancer
- Recurrent Head and Neck Cancer
- Bempegaldesleukin
- Pembrolizumab
- (no location specified)
2021-09-28
Sep 28, 2021M
Not yet recruiting
- Lung Cancer, Nonsmall Cell
- Pembrolizumab
- +3 more
- (no location specified)
2021-05-07
May 7, 2021A
Not yet recruiting
- Non Hodgkin Lymphoma
- Pembrolizumab
- (no location specified)
2021-09-14
Sep 14, 2021A
P
Recruiting
- Breast Cancer
- Pembrolizumab
- High-intensity focused ultrasound (HIFU)
- Charlottesville, VirginiaUniversity of Virginia
2021-08-11
Aug 11, 2021A
Active, not recruiting
- Malignant Melanoma
- pembrolizumab
- Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
2021-09-24
Sep 24, 2021T
Terminated
- Metastatic Colorectal Cancer
- Napabucasin
- Pembrolizumab
- Kashiwa, Chiba, JapanNational Cancer Center Hospital East
2021-08-30
Aug 30, 2021M
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- Docetaxel
- (no location specified)
2021-09-07
Sep 7, 2021J
Recruiting
- Pancreatic Cancer
- Cabozantinib
- Pembrolizumab
- Lexington, KentuckyUniversity of Kentucky Markey Cancer Center
2021-10-07
Oct 7, 2021I
Not yet recruiting
- Lymphoma, Extranodal NK-T-Cell
- Pembrolizumab
- Involved Field Radiation Therapy
- Shanghai, ChinaShanghai Rui-Jin Hospital
2021-08-27
Aug 27, 2021U
Recruiting
- Pleural Mesothelioma
- Pembrolizumab
- Cisplatin and Pemetrexed
- Chicago, IllinoisUniversity of Chicago
2021-06-29
Jun 29, 2021E
Active, not recruiting
- Transitional Cell Carcinoma of the Bladder
- Biomarkers
- Pembrolizumab
- Rotterdam, NetherlandsErasmus MC
2021-08-19
Aug 19, 2021M
Completed
- Urothelial Cancer
- pembrolizumab
- +3 more
- (no location specified)
2021-08-23
Aug 23, 2021P
Suspended
- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma
- GR-MD-02
- +2 more
- Portland, OregonPortland Providence Medical Center
2021-09-23
Sep 23, 2021G
Not yet recruiting
- Nasopharyngeal Carcinoma
- Pembrolizumab
- (no location specified)
2021-03-29
Mar 29, 2021C
Recruiting
- NPC
- Pembrolizumab
- Hong Kong, Hong Kong
- +1 more
2021-07-26
Jul 26, 2021Y
Recruiting
- Advanced Metastatic Melanoma
- Cabozantinib
- Pembrolizumab
- Iowa City, IowaUniversity of Iowa Hospitals and Clinics
2021-09-13
Sep 13, 2021S
Terminated
- Patients With Leptomeningeal Disease
- Pembrolizumab
- Baltimore, MarylandJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
2021-01-06
Jan 6, 2021C
Recruiting
- Acral Lentiginous Melanoma
- pembrolizumab
- Hong Kong, Hong KongDepartment of Clinical Oncology, Prince of Wales Hospital
2021-07-26
Jul 26, 2021M
Completed
- Hepatocellular Carcinoma
- Pembrolizumab
- +2 more
- (no location specified)
2021-09-20
Sep 20, 2021D
U
Recruiting
- Rectum Cancer
- Rectal Cancer
- Pembrolizumab
- Geneva, SwitzerlandHôpitaux Universitaires de Genève
2021-09-29
Sep 29, 2021M
Completed
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- pembrolizumab
- +3 more
- (no location specified)
2021-07-29
Jul 29, 2021